Theriva Biologics, Inc. (TOVX)
0.196
+0.01
(+3.16%)
USD |
NYAM |
Oct 23, 16:00
0.1916
0.00 (0.00%)
After-Hours: 20:00
Theriva Biologics Net Income (Quarterly) : -3.217M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.217M |
| March 31, 2026 | -2.044M |
| December 31, 2025 | -1.996M |
| September 30, 2025 | -4.361M |
| June 30, 2025 | -13.06M |
| March 31, 2025 | -4.324M |
| December 31, 2024 | -4.447M |
| September 30, 2024 | -7.726M |
| June 30, 2024 | -8.316M |
| March 31, 2024 | -5.165M |
| December 31, 2023 | -5.485M |
| September 30, 2023 | -3.303M |
| June 30, 2023 | -5.084M |
| March 31, 2023 | -4.478M |
| December 31, 2022 | -5.591M |
| September 30, 2022 | -4.83M |
| June 30, 2022 | -4.477M |
| March 31, 2022 | -4.273M |
| December 31, 2021 | -5.263M |
| September 30, 2021 | -3.273M |
| June 30, 2021 | -3.195M |
| March 31, 2021 | -2.537M |
| December 31, 2020 | -2.132M |
| September 30, 2020 | -2.111M |
| June 30, 2020 | -2.883M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.99M |
| December 31, 2019 | -3.144M |
| September 30, 2019 | -5.15M |
| June 30, 2019 | -3.558M |
| March 31, 2019 | -3.528M |
| December 31, 2018 | -3.192M |
| September 30, 2018 | -3.689M |
| June 30, 2018 | -4.214M |
| March 31, 2018 | -2.326M |
| December 31, 2017 | 2.812M |
| September 30, 2017 | -10.93M |
| June 30, 2017 | -4.315M |
| March 31, 2017 | -3.058M |
| December 31, 2016 | -2.472M |
| September 30, 2016 | -8.489M |
| June 30, 2016 | -5.764M |
| March 31, 2016 | -11.08M |
| December 31, 2015 | -11.30M |
| September 30, 2015 | -7.507M |
| June 30, 2015 | -13.62M |
| March 31, 2015 | -12.36M |
| December 31, 2014 | -6.48M |
| September 30, 2014 | -4.91M |
| June 30, 2014 | -4.556M |
| March 31, 2014 | -3.838M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.217M |
| EPS Diluted (Quarterly) | -0.0701 |
| Enterprise Value | 1.211M |
| Earnings Yield | -341.2% |
| Normalized Earnings Yield | -348.72 |